Description:
- Antiviral drugs
- Effective against Covid-19
Abstract
USC researchers engineered nanoscale barriers capable of lipid interactions with viruses, thus interfering with membrane fusion, and membrane remodeling preventing viral entry and replication. The HPBCD-based platform can safely interact with existing mucocutaneous protective barriers capable of preventing a wide spectrum of microbial intrusion and promote their clearance.
Benefit
- Effective against Covid-19
Market Application
Market Opportunity:
The human nasal, oropharyngeal and to a lesser extent ocular system are the major gateways for microbial entry into the body, and if not eliminated, can lead to systemic infections by bacteria and viruses. Our investigators found that an engineered nanoscale biocompatible coating capable of enhancing the mucocutaneous lining found in conjunctival, nasal and oropharyngeal passages has the potential to be effective in preventing microbial attachment onto epithelial cells, thus blocking microbial entry and infection.
Publications
Other
- Available for exclusive and non-exclusive license
- IP Status: US Patent pending